
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments Corp experienced a significant 53% year-over-year growth in Medicare Advantage membership, which is pivotal as this segment accounts for approximately 97% of its total membership. The adoption of Clover Assistant is expected to enhance medical cost ratios, thereby improving unit economics and contribution margin as new members join in 2026. Additionally, the company anticipates financial benefits from its 4-star plan rating and favorable CMS rate updates, projecting an increase in new member revenue that exceeds $70 per member per month, further solidifying a positive financial outlook.
Bears say
Clover Health Investments Corp exhibits several concerns that contribute to a negative outlook on its stock performance. Despite a maintained adjusted EBITDA of $22.6 million amid a 33% increase in average Medicare Advantage (MA) membership, the company faces potential challenges in maintaining its 4-Star rating, which could adversely affect future medical loss ratio (MLR) and earnings metrics. Additionally, the upcoming 2026 guidance signals a decrease in gross profit margins due to dilution from new members and is further clouded by regulatory changes and heightened competition in the Medicare Advantage market.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares